References | Years | Location | Study design | Sample size | Mean age | Female | Follow-up times (months) | Outcomes | |||
---|---|---|---|---|---|---|---|---|---|---|---|
KA | MA | KA | MA | KA | MA | ||||||
Kaneda [35] | 2021 | Japan | RCT | 8 | 2 | 76.3 | 75 | NA | 5 | 12 | HKA, mLDFA, mMPTA,FFA,TS |
Matsumoto [29] | 2020 | Japan | RCT | 30 | 30 | 74.2 | 75.5 | 25 | 26 | 12 | HKA, mLDFA, mMPTA, KSS, ROM |
Young [25] | 2020 | New Zealand | RCT | 47 | 48 | NA | NA | NA | NA | 60 | KSS, WOMAC, OKS, EQ-5D, FJ, Complication |
MacDessi [31] | 2020 | Australia | RCT | 70 | 68 | 67.4 | 69.0 | 40 | 34 | 12 | HKA, mLDFA, mMPTA, KOOS, EQ-5D, FJS, OT |
McEwen [28] | 2020 | New Zealand | RCT | 41 | 41 | NA | NA | NA | NA | 24 | HKA, mLDFA, mMPTA, JLOA, FFA,TS, ROM, KOOS, OKS, FJS, Complication |
Laende [32] | 2019 | Canada | RCT | 24 | 23 | 64 | 63 | 16 | 17 | 24 | HKA, mMPTA, OKS |
Yeo [26] | 2018 | South Korea | RCT | 30 | 30 | 72 | 74 | 25 | 27 | 96 | HKA, mLDFA, mMPTA, FFA, TS,WOMAC, ROM |
Matsumoto [30] | 2017 | Japan | RCT | 30 | 30 | 75.3 | 76.1 | 18 | 20 | 24 | HKA, JLOA, KSS, ROM |
Waterson [27] | 2016 | United Kingdom | RCT | 36 | 35 | NA | NA | NA | NA | 12 | KSS, ROM, EQ-5D |
Calliess [33] | 2016 | Germany | RCT | 100 | 100 | 67 | 70 | 61 | 57 | 12 | HKA, mLDFA, mMPTA, FFA, TS, WOMAC, Complication |
Young [24] | 2016 | New Zealand | RCT | 49 | 50 | 72 | 70 | 24 | 24 | 24 | HKA, FKA, mLDFA, mMPTA, TS, KSS, WOMAC, ROM, OKS, EQ-5D, FJS, OT, WL, HS, Complication |
Belvedere [34] | 2015 | Italy | RCT | 6 | 11 | NA | NA | NA | NA | 6 | KSS |
Dossett [20] | 2014 | United States | RCT | 44 | 44 | 66 | 66 | 3 | 6 | 24 | HKA, FKA, mLDFA, mMPTA, JLOA, KSS, WOMAC, ROM, OKS, HS,CHb,WD, Complication |
Dossett [19] | 2012 | United States | RCT | 41 | 41 | 65 | 66 | 2 | 6 | 6 | HKA, FKA, mLDFA, mMPTA, JLOA, FFA, TS, KSS, WOMAC, ROM, OKS, Complication, OT, WL, HS, CHb, WD |